Compare MRAM & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | ASRT |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | 85 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.3M | 76.0M |
| IPO Year | 2016 | 2004 |
| Metric | MRAM | ASRT |
|---|---|---|
| Price | $8.78 | $13.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 419.8K | 42.2K |
| Earning Date | 03-04-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $49,417,000.00 | ★ $118,713,000.00 |
| Revenue This Year | $10.87 | N/A |
| Revenue Next Year | $8.33 | $16.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $4.34 | $0.51 |
| 52 Week High | $17.24 | $13.90 |
| Indicator | MRAM | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 66.87 |
| Support Level | $8.42 | $0.69 |
| Resistance Level | $9.74 | N/A |
| Average True Range (ATR) | 0.56 | 0.65 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 6.20 | 78.95 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.